<![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC ]]>

Key Takeaways From the Phase 1 StudyThe novel long-circulating PSMA therapeutic radioligand [177Lu]Lu-D-Dan-Phe-PSMA was well tolerated across all dose levels and delivered high tumor-absorbed radiation doses with prolonged tumor retention in patients with mCRPC.In the 3.70 GBq-cohort (n = 3), all 3 patients experienced PSA reduction after 2 treatment cycles, with 66.7% achieving at least a 50% PSA decline.No DLTs were observed in any activity group during the 42-day observation period, and no immediate or life-threatening serious adverse effects were reported.